Teva Completes Acquisition of Theramex

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Teva Pharmaceutical Industries Ltd. announced that it has completed the acquisition of Theramex, Merck KGaA’s European-based women’s health business.

Acquisition Provides Teva with a Strong Platform to Expand its Global Women’s Health Franchise

Theramex brings to Teva a broad portfolio of women’s health and gynecology products sold in over 50 countries, primarily France and Italy. Theramex’s pipeline includes NOMAC/E2, a new oral contraceptive based on natural estrogens, which has successfully completed phase III studies and was submitted for approval in Europe.

Latest stories

Previous article

Novartis drug Tasigna received approval from the European Commission

Next article

Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

MORE STORIES